Pfizer backs retina stem cell research

Article

Pfizer is to fund research into the application of stem cells in degenerative retinal disease through a $3 million investment in EyeCyte, a company based in California, US.

Pfizer is to fund research into the application of stem cells in degenerative retinal disease through a $3 million investment in EyeCyte, a company based in California, US.

EyeCyte, a spin-off of the laboratory of Professor Martin Friedlander, MD, PhD at the Scripps Research Institute, is currently investigating the role of stem and progenitor cells in the treatment of diabetic retinopathy. Other acquired and inherited retinal diseases the company is investigating include age-related macular degeneration, retinopathy of prematurity, retinal vascular occlusive disease and retinitis pigmentosa.

Professor Friedlander's research, funded by grants from the National Eye Institute (NEI) and the National Institutes of Health (NIH), has demonstrated that stem cells and progenitor cells can target neovascularization and halt the degeneration of the vasculature in animal models.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.